Skip to content

Evaluation of the Wear of Vitamin E Treated Polyethylene Components in Primary THA Using RSA

Evaluation of the Wear of Vitamin E Treated Polyethylene Components in Primary Total Hip Arthroplasty Using Radiostereometric Analysis (RSA)

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00551967
Enrollment
50
Registered
2007-11-01
Start date
2007-10-31
Completion date
2022-12-31
Last updated
2017-05-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis of Hip, Traumatic Arthritis of Hip

Keywords

clinical outcomes, radiographic outcomes, total hip arthroplasty, survivorship

Brief summary

The specific aim of this proposed study is to conduct a prospective RSA clinical study at Massachusetts General Hospital involving 50 patients receiving primary total hip replacements. All patients will receive the vitamin E treated polyethylene acetabular inserts. Short-term femoral head penetration and long-term steady state wear of the polyethylene will be measured using both RSA and Martell analysis techniques. Stability of the acetabular and femoral components will be measured in all patients using RSA analysis. The stability of the cemented femoral stems will be compared to the stability of the cementless femoral components as well as to historic data in the literature. In addition, all patients will complete a self-administered questionnaire to assess the clinical outcome of the surgery and patient satisfaction.

Interventions

PROCEDUREHip replacement

Surgical implantation of hip replacement components for the treatment of osteoarthritis

Sponsors

Zimmer Biomet
CollaboratorINDUSTRY
Massachusetts General Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Male or female * 20 to 75 years of age * Subjects requiring primary total hip replacement * Subjects with diagnosis of osteoarthritis, avascular necrosis, or traumatic arthritis * Subjects who demonstrate the ability to return to MGH for follow-up for the next five years.

Exclusion criteria

* Subjects with limited life span * Subjects with difficulty in comprehending study protocol for any reason. * Subjects with inflammatory disease, previous infection or those requiring revision hip surgery. * Subjects whose bony structures are so small that a femoral head less than 32mm in diameter must be used. * Subjects whose bony structure deviates substantially from the general norm sufficiently to require non-standard techniques and non-standard implants. Specific examples of these are total dislocation of the hip, severe coxa vera deformity, severe forms of multiple epiphyseal dysplasia * Subjects with complex disease entities which significantly increase the risks of the surgery such as any major platelet abnormality, hematological disorder, positive for HIV or any other major medical complication which substantially reduces longevity. * Female subjects that are pregnant or who may suspect they are pregnant or who plan to become pregnant while participating in this study.

Design outcomes

Primary

MeasureTime frame
Short-term femoral head penetration,long-term steady state wear of polyethylene. Stability of acetabular & femoral components. Clinical questionnaires to assess preop,clinical outcomes,& patient satisfaction.5 years

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026